BioCentury
ARTICLE | Clinical News

Firdapse: Ph II/III data

March 17, 2017 1:02 PM UTC

Top-line data from a double-blind, crossover, Italian Phase II/III trial in 7 MUSK-MG patients showed that dose-titrated Firdapse met the co-primary endpoints of improving QMG and MG-ADL total scores ...